S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Sage Therapeutics Stock Forecast, Price & News

-0.02 (-0.06%)
(As of 07/1/2022 05:44 PM ET)
Today's Range
50-Day Range
52-Week Range
422,510 shs
Average Volume
759,085 shs
Market Capitalization
$1.91 billion
P/E Ratio
Dividend Yield
Price Target

Sage Therapeutics Stock Forecast (MarketRank)

Analyst Rating
2.43 Rating Score
74.9% Upside
$56.47 Price Target
Short Interest
6.16% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.89mentions of Sage Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$251.60 K Bought Last Quarter
Proj. Earnings Growth
From ($8.76) to ($7.52) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.33 out of 5 stars

Medical Sector

202nd out of 1,429 stocks

Pharmaceutical Preparations Industry

80th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Sage Therapeutics logo

About Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
$-457.89 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$6.31 million
Book Value
$29.35 per share


Free Float
Market Cap
$1.91 billion

Sage Therapeutics Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2022?

14 analysts have issued 12 month price objectives for Sage Therapeutics' stock. Their SAGE stock forecasts range from $37.00 to $85.00. On average, they expect Sage Therapeutics' share price to reach $56.47 in the next year. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for Sage Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Sage Therapeutics' stock performed in 2022?

Sage Therapeutics' stock was trading at $42.54 at the beginning of 2022. Since then, SAGE stock has decreased by 24.1% and is now trading at $32.28.
View the best growth stocks for 2022 here

When is Sage Therapeutics' next earnings date?

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Sage Therapeutics

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, May, 3rd. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating analysts' consensus estimates of ($2.09) by $0.02. The biopharmaceutical company had revenue of $1.58 million for the quarter, compared to analysts' expectations of $3.23 million. Sage Therapeutics had a negative net margin of 7,676.91% and a negative trailing twelve-month return on equity of 27.23%. The firm's revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the company earned ($1.64) EPS.
View Sage Therapeutics' earnings history

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the following people:
  • Mr. Barry E. Greene, Pres, CEO & Director (Age 59, Pay $1.25M) (LinkedIn Profile)
  • Ms. Kimi E. Iguchi CPA, CFO & Treasurer (Age 60, Pay $621.17k)
  • Dr. Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 61, Pay $661.68k)
  • Dr. Jeffrey M. Jonas M.D., Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 69, Pay $923.01k)
  • Mr. Christopher Benecchi, Chief Commercial Officer (Age 50, Pay $389.35k)
  • Mr. Matt Lasmanis, Chief Technology & Innovation Officer
  • Helen Rubinstein, Investor Relations Officer
  • Ms. Anne Marie Cook Esq., Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Ms. Erin E. Lanciani, Chief People & Experience Officer (Age 53)
  • Dr. Amy Schacterle Ph.D., Sr. VP of R&D Strategy and Bus. Management

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How do I buy shares of Sage Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $32.28.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $1.91 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457.89 million in net income (profit) each year or ($8.23) on an earnings per share basis.

How many employees does Sage Therapeutics have?

Sage Therapeutics employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for Sage Therapeutics is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at [email protected], or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.